HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025 - OncoDaily HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025 / cancer, ESMO, ESMO Breast 2025, Oncology, radiation

HYPART Trial: Testing 1-Week vs. 2-Week Radiotherapy for High-Risk Breast Cancer at ESMO Breast 2025
@myesmo.bsky.social

oncodaily.com/blog/hypart-...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #HYPART #ESMOBreast25